Theravance Biopharma (TBPH) Free Cash Flow Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Theravance Biopharma | 823.54 Mn | 428.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.76% |
| Dec 31, 2025 | 37.98% |
| Sep 30, 2025 | 39.32% |
| Jun 30, 2025 | 41.81% |
| Mar 31, 2025 | 22.58% |
| Dec 31, 2024 | 55.93% |
| Sep 30, 2024 | 34.94% |
| Jun 30, 2024 | 38.01% |
| Mar 31, 2024 | 57.72% |
| Dec 31, 2023 | 50.91% |
| Sep 30, 2023 | 45.23% |
| Jun 30, 2023 | 26.66% |
| Mar 31, 2023 | -17.70% |
| Dec 31, 2022 | -22.83% |
| Sep 30, 2022 | 18.67% |
| Jun 30, 2022 | 20.41% |
| Mar 31, 2022 | 12.26% |
| Dec 31, 2021 | -8.50% |
| Sep 30, 2021 | -29.33% |
| Jun 30, 2021 | -8.93% |
| Mar 31, 2021 | -21.55% |
| Dec 31, 2020 | -14.01% |
| Sep 30, 2020 | -19.35% |
| Jun 30, 2020 | -3.32% |
| Mar 31, 2020 | 0.39% |
| Dec 31, 2019 | -8.68% |
| Sep 30, 2019 | -3.94% |
| Jun 30, 2019 | 1.23% |
| Mar 31, 2019 | -12.17% |
| Dec 31, 2018 | -8.17% |
| Sep 30, 2018 | -8.92% |
| Jun 30, 2018 | -20.13% |
| Mar 31, 2018 | 29.27% |